Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on developing therapies to treat T cell-driven inflammatory diseases.

The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets.

Its lead product candidate is CBP-201, an antibody to target interleukin-4 receptor alpha in development for the treatment of atopic dermatitis (AD) and asthma.

The company's product candidates also comprise CBP-307, a modulator of S1P1 T cell receptor and is in development for the treatment of ulcerative colitis; and CBP-174, a peripherally acting antagonist of histamine receptor 3 in development for the treatment of pruritus associated with skin inflammation.

Connect Biopharma Holdings Limited was founded in 2012 and is headquartered in San Diego, California.